Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-08T01:26:51.442Z Has data issue: false hasContentIssue false
  • English
  • Français

Biomarkers predicting chemotherapy response in head and neck squamous cell carcinoma: a review

Published online by Cambridge University Press:  02 October 2015

B Cosway ,
V Paleri  and
J Wilson
B Cosway*
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Freeman Hospital, Newcastle upon Tyne, UK
V Paleri
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Freeman Hospital, Newcastle upon Tyne, UK
J Wilson
Affiliation:
Department of Otolaryngology – Head and Neck Surgery, Freeman Hospital, Newcastle upon Tyne, UK
*
Address for correspondence: Mr Benjamin Cosway, Department of Otolaryngology – Head and Neck Surgery, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK E-mail: benjamin.cosway@newcastle.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Biomarkers are increasingly being used in many cancers to select patients for oncological treatment paradigms based on their inherent genetic properties. However, in head and neck cancers, there are no personalised therapies available outside the context of a clinical trial. A number of studies suggest there are intrinsic tumour properties of head and neck cancers that affect their response to chemotherapeutic agents. This paper aimed to review their evidence base.

Method:

A narrative review was conducted following a search of the PubMed database.

Results and conclusion:

The review identified a number of biomarkers predicting response to chemotherapy in head and neck cancers. The paper discusses these in detail, and explores where future research could be directed in order to deliver personalised therapies for patients with head and neck cancers.

Keywords

Otorhinolaryngological NeoplasmsInduction ChemotherapyBiological Markers
Type
Review Articles
Information
The Journal of Laryngology & Otology , Volume 129 , Issue 11 , November 2015 , pp. 1046 - 1052
Copyright
Copyright © JLO (1984) Limited 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Slamon, DJ, Leyland-Jones, B, Shak, S, Fuchs, H, Paton, V, Bajamonde, A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92CrossRefGoogle Scholar
2Lievre, A, Bachet, J-B, Le Corre, D, Boige, V, Landi, B, Emile, J-F et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992–5CrossRefGoogle ScholarPubMed
3Chapman, PB, Hauschild, A, Robert, C, Haanen, JB, Ascierto, P, Larkin, J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507–16CrossRefGoogle ScholarPubMed
4Rainsbury, JW, Ahmed, W, Williams, HK, Roberts, S, Paleri, V, Mehanna, H. Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: systematic review and meta-analysis. Head Neck 2013;35:1048–55CrossRefGoogle ScholarPubMed
5UK Clinical Research Network: Portfolio Database. Improving treatment selection using predictive and prognostic classifiers of treatment response for head and neck cancers and dysplasia (PREDICTR-HNC). In: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=11317 [22 March 2014]Google Scholar
6Fakhry, C, Westra, WH, Li, S, Cmelak, A, Ridge, JA, Pinto, H et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261–9CrossRefGoogle ScholarPubMed
7O'Rorke, MA, Ellison, MV, Murray, LJ, Moran, M, James, J, Anderson, LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 2012;48:1191–201CrossRefGoogle ScholarPubMed
8UK Clinical Research Network: Portfolio Database. De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oropharyngeal squamous cell carcinoma. In: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=11723 [11 February 2014]Google Scholar
9Cabelguenne, A, Blons, H, de Waziers, I, Carnot, F, Houllier, AM, Soussi, T et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000;18:1465–73CrossRefGoogle ScholarPubMed
10Temam, S, Flahault, A, Perie, S, Monceaux, G, Coulet, F, Callard, P et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000;18:385–94CrossRefGoogle ScholarPubMed
11Perrone, F, Bossi, P, Cortelazzi, B, Locati, L, Quattrone, P, Pierotti, MA et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J Clin Oncol 2010;28:761–6CrossRefGoogle ScholarPubMed
12Mroz, EA, Rocco, JW. Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer. J Clin Oncol 2010;28:715–17CrossRefGoogle ScholarPubMed
13Perisanidis, C, Perisanidis, B, Wrba, F, Brandstetter, A, El Gazzar, S, Papadogeorgakis, N et al. Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 2012;41:40–6CrossRefGoogle ScholarPubMed
14Kumar, B, Cordell, KG, D'Silva, N, Prince, ME, Adams, ME, Fisher, SG et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2008;134:363–9CrossRefGoogle ScholarPubMed
15Kumar, B, Cordell, KG, Lee, JS, Worden, FP, Prince, ME, Tran, HH et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26:3128–37CrossRefGoogle ScholarPubMed
16Etienne, MC, Pivot, X, Formento, JL, Bensadoun, RJ, Formento, P, Dassonville, O et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 1999;79:1864–9CrossRefGoogle ScholarPubMed
17Hitt, R, Ciruelos, E, Amador, ML, Benito, A, Sanchez, JJ, Ballestin, C et al. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Eur J Cancer 2005;41:453–60CrossRefGoogle ScholarPubMed
18Pivot, X, Magne, N, Guardiola, E, Poissonnet, G, Dassonville, O, Francoual, M et al. Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol 2005;41:320–7CrossRefGoogle ScholarPubMed
19Licitra, L, Mesia, R, Rivera, F, Remenar, E, Hitt, R, Erfán, J et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2011;22:1078–87CrossRefGoogle ScholarPubMed
20Kalyankrishna, S, Grandis, JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666–72CrossRefGoogle ScholarPubMed
21Zhou, X, Zhang, Z, Yang, X, Chen, W, Zhang, P. Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity. Int J Cancer 2009;124:483–9CrossRefGoogle ScholarPubMed
22Feng, Z, Guo, W, Zhang, C, Xu, Q, Zhang, P, Sun, J et al. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS One 2011;6:e26399CrossRefGoogle ScholarPubMed
23Akervall, J, Brun, E, Dictor, M, Wennerberg, J. Cyclin D1 overexpression versus response to induction chemotherapy in squamous cell carcinoma of the head and neck–preliminary report. Acta Oncol 2001;40:505–11CrossRefGoogle ScholarPubMed
24Ishiguro, R, Fujii, M, Yamashita, T, Tashiro, M, Tomita, T, Ogawa, K et al. CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma. Anticancer Res 2003;23:5213–20Google ScholarPubMed
25Nogales, E. Structural insights into microtubule function. Ann Rev Biochem 2000;69:277–302CrossRefGoogle ScholarPubMed
26Berrieman, HK, Lind, MJ, Cawkwell, L. Do β-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004;5:158–64CrossRefGoogle ScholarPubMed
27Cullen, KJ, Schumaker, L, Nikitakis, N, Goloubeva, O, Tan, M, Sarlis, NJ et al. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J Clin Oncol 2009;27:6222–8CrossRefGoogle ScholarPubMed
28Koh, Y, Kim, TM, Jeon, YK, Kwon, TK, Hah, JH, Lee, SH et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 2009;20:1414–19CrossRefGoogle ScholarPubMed
29Sève, P, Isaac, S, Trédan, O, Souquet, P-J, Pachéco, Y, Pérol, M et al. Expression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005;11:5481–6CrossRefGoogle ScholarPubMed
30Roque, DM, Bellone, S, Buza, N, Romani, C, Cocco, E, Bignotti, E et al. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. Am J Obstet Gynecol 2013;209:62.e1–9CrossRefGoogle ScholarPubMed
31Tulub, AA, Stefanov, VE. Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. Int J Biol Macromol 2001;28:191–8CrossRefGoogle ScholarPubMed
32Ziliak, D, O'Donnell, PH, Im, HK, Gamazon, ER, Chen, P, Delaney, S et al. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 2011;157:265–72CrossRefGoogle Scholar
33Huang, RS, Johnatty, SE, Gamazon, ER, Im, HK, Ziliak, D, Duan, S et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 2011;17:5490–500CrossRefGoogle Scholar
34Teknos, TN, Cox, C, Barrios, MA, Chepeha, DB, Bradford, CR, Fisher, SG et al. Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. Laryngoscope 2002;112:844–51CrossRefGoogle ScholarPubMed
35Rueda, A, Cazorla, O, Perez, L, Alvarez, M, Redondo, M, Gallego, E et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation. Head Neck 2011;33:808–16CrossRefGoogle ScholarPubMed
36Kyzas, PA, Cunha, IW, Ioannidis, JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005;11:1434–40CrossRefGoogle ScholarPubMed
37Nordsmark, M, Bentzen, SM, Rudat, V, Brizel, D, Lartigau, E, Stadler, P et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18–24CrossRefGoogle ScholarPubMed
38Nishimura, T, Newkirk, K, Sessions, RB, Andrews, PA, Trock, BJ, Rasmussen, AA et al. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 1996;2:1859–65Google ScholarPubMed
39Cabelguenne, A, Loriot, MA, Stucker, I, Blons, H, Koum-Besson, E, Brasnu, D et al. Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer 2001;93:725–30CrossRefGoogle ScholarPubMed
40Shiga, H, Heath, EI, Rasmussen, AA, Trock, B, Johnston, PG, Forastiere, AA et al. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 1999;5:4097–104Google ScholarPubMed
41Blons, H, Gad, S, Zinzindohoue, F, Maniere, I, Beauregard, J, Tregouet, D et al. Matrix metalloproteinase 3 polymorphism: a predictive factor of response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. Clin Cancer Res 2004;10:2594–9CrossRefGoogle ScholarPubMed
42Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47CrossRefGoogle ScholarPubMed
43Patterson, JM, McColl, E, Carding, PN, Hildreth, AJ, Kelly, C, Wilson, JA. Swallowing in the first year after chemoradiotherapy for head and neck cancer: clinician- and patient-reported outcomes. Head Neck 2014;36:352–8CrossRefGoogle ScholarPubMed
44Paleri, V, Wight, RG, Silver, CE, Haigentz, M Jr, Takes, RP, Bradley, PJ et al. Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol 2010;46:712–19CrossRefGoogle ScholarPubMed
45Weber, RS, Berkey, BA, Forastiere, A, Cooper, J, Maor, M, Goepfert, H et al. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg 2003;129:44–9CrossRefGoogle ScholarPubMed
46Forastiere, AA, Zhang, Q, Weber, RS, Maor, MH, Goepfert, H, Pajak, TF et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31:845–52CrossRefGoogle ScholarPubMed
47Paydarfar, JA, Birkmeyer, NJ. Complications in head and neck surgery: a meta-analysis of postlaryngectomy pharyngocutaneous fistula. Arch Otolaryngol Head Neck Surg 2006;132:67–72CrossRefGoogle ScholarPubMed
48Hamilton, D, Bins, JE, McMeekin, PJ, Thomson, RG, Paleri, V, Wilson, JA. Quality compared to quantity of life in laryngeal cancer: a time trade-off study. Head Neck 2015. Epub 2015 Mar 31Google ScholarPubMed
49O'Hara, J, Cosway, B, Muirhead, C, Leonard, N, Goff, D, Patterson, J. Transoral laser microsurgery ± adjuvant therapy versus chemoradiotherapy for stage III and IVA oropharyngeal squamous cell cancer: preliminary comparison of early swallowing outcomes. Head Neck 2014. Epub 2014 May 31Google Scholar